Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP – Get Free Report) had its price objective raised by equities research analysts at HC Wainwright from $8.00 to $21.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 311.76% from the stock’s previous close.
Neuphoria Therapeutics Inc. – Common Stock Stock Performance
NASDAQ:NEUP opened at $5.10 on Tuesday. Neuphoria Therapeutics Inc. – Common Stock has a one year low of $2.12 and a one year high of $16.08.
Neuphoria Therapeutics Inc. – Common Stock Company Profile
Featured Stories
- Five stocks we like better than Neuphoria Therapeutics Inc. – Common Stock
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Cigna Misses EPS: What It Means for the Health Insurance Industry
- The Most Important Warren Buffett Stock for Investors: His Own
- Saia Builds Value: Why Its Uptrend Is Set to Continue
- Stock Analyst Ratings and Canadian Analyst Ratings
- T-Mobile: The Best Wireless Carrier Stock to Own Right Now?
Receive News & Ratings for Neuphoria Therapeutics Inc. - Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics Inc. - Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
